Last updated: October 29, 2026
Amphadase is a mature, niche hyaluronidase product marketed by Amphastar Pharmaceuticals. Its commercial value is tied to hospital and outpatient procedural use, including subcutaneous fluid administration and dispersion or absorption of injected drugs. Public filings do not disclose Amphadase revenue separately, so product-level growth, margin, and market-share calculations are unavailable. The product remains commercially relevant but is unlikely to be a major driver of Amphastar’s consolidated financial performance.
What is Amphadase and how is it used?
Amphadase is an injectable preparation of purified bovine hyaluronidase. It temporarily increases tissue permeability by hydrolyzing hyaluronic acid in the extracellular matrix. The effect facilitates the dispersion and absorption of co-administered fluids and injected medicines.
The FDA-approved label identifies three principal uses:
- Subcutaneous fluid administration, including hypodermoclysis
- Dispersion and absorption of other injected drugs
- Subcutaneous urography in selected radiographic procedures
Amphadase is supplied at 150 USP units/mL. It is administered subcutaneously, intramuscularly, or intradermally depending on the clinical use. Intravenous administration is not appropriate because hyaluronidase is rapidly inactivated in the bloodstream. The label also warns about hypersensitivity reactions, particularly with animal-derived products. (U.S. Food and Drug Administration [FDA], 2004)
How does Amphadase compare with competing hyaluronidase products?
The principal branded comparator is Hylenex recombinant, marketed by Halozyme Therapeutics. Hylenex contains recombinant human hyaluronidase PH20, while Amphadase is derived from bovine tissue.
| Attribute |
Amphadase |
Hylenex recombinant |
| Active ingredient |
Bovine hyaluronidase |
Recombinant human hyaluronidase PH20 |
| Strength |
150 USP units/mL |
150 USP units/mL |
| Regulatory product type |
FDA-approved drug product under NDA |
FDA-approved recombinant product |
| Primary manufacturer |
Amphastar Pharmaceuticals |
Halozyme Therapeutics |
| Key differentiation |
Established animal-derived product; potentially lower acquisition cost |
Recombinant human origin; broader commercial positioning |
| Main risk factor |
Animal-protein hypersensitivity and supply or procurement preference |
Higher price and dependence on branded supply |
| Primary buyers |
Hospitals, clinics, procedural sites, pharmacies |
Hospitals, specialty practices, pharmacies |
Vitrase, another bovine hyaluronidase product, is not a meaningful current competitive force after its commercial withdrawal. The market therefore has a concentrated structure, with Amphadase competing mainly against Hylenex and institutional purchasing alternatives.
What is the FDA regulatory status of Amphadase?
Amphadase was approved by the FDA in 2004 under NDA 021664. The product is a legacy injectable drug with a long post-approval history rather than a recently launched biologic. Its approval is supported by established clinical use of hyaluronidase and by the product’s labeled administration procedures. (FDA, 2004)
Amphadase is not a biosimilar. It does not compete through the abbreviated biosimilar pathway used for reference biologics. A competing manufacturer would generally need to establish its own regulatory basis for an equivalent hyaluronidase product rather than rely on automatic substitution under the biosimilar framework.
The product’s age reduces the likelihood of meaningful remaining regulatory exclusivity. Market access is governed primarily by manufacturing capability, FDA compliance, hospital formulary decisions, supply reliability, and commercial pricing.
What is the Orange Book status of Amphadase?
Amphadase is an FDA-approved prescription product with a mature regulatory record. The commercial importance of Orange Book protection is limited because the product was approved more than 20 years ago and no meaningful period of new-drug exclusivity remains.
The principal commercial protections are therefore operational rather than exclusivity-based:
- FDA-compliant manufacture of a sterile injectable enzyme
- Reliable sourcing and control of bovine-derived raw material
- Validated purification and viral or adventitious-agent controls
- Stability and container-closure performance
- Hospital purchasing relationships
- Distribution continuity
A current FDA Orange Book search should be used for any transaction or litigation diligence involving active patent certifications. Amphadase’s commercial position does not appear to depend on a recent Orange Book patent estate. (FDA, n.d.-a)
When did Amphadase lose exclusivity?
Amphadase’s statutory new-drug exclusivity expired long ago. The product’s approval in 2004 places it outside the normal five-year new chemical entity exclusivity period and outside the three-year exclusivity period associated with certain supplemental clinical investigations.
Any remaining commercial exclusivity would have to come from active listed patents, regulatory restrictions, manufacturing complexity, or market access barriers. Publicly available product information does not indicate that Amphadase currently benefits from a material patent-based monopoly.
This distinction matters because a product can remain commercially viable after exclusivity ends if the market is small, supply is technically difficult, and incumbent manufacturers have established purchasing channels. Amphadase fits that profile more closely than the profile of a high-growth protected biologic.
How large is the Amphadase market?
The addressable market is narrow and fragmented. Hyaluronidase is used as an adjunct rather than as the primary treatment for a disease. Demand depends on procedure volumes, institutional protocols, clinician familiarity, and reimbursement or acquisition economics.
The main demand segments are:
- Subcutaneous fluid administration when intravenous access is difficult or undesirable.
- Dispersion of injected medications and local anesthetic-related procedures.
- Subcutaneous urography and selected diagnostic applications.
- Specialty and office-based procedures where hyaluronidase is incorporated into treatment protocols.
The product does not have the demand characteristics of a chronic therapy. It is not taken daily by a large patient population, and its utilization is sensitive to hospital policies and substitution by alternative administration techniques.
What market forces affect Amphadase demand?
Several forces shape the product’s market:
- Hospital conversion to recombinant hyaluronidase products
- Price differences between Amphadase and Hylenex
- Concerns regarding bovine-derived proteins
- Availability of trained staff and alternative vascular-access procedures
- Procedure volumes in emergency, oncology, ophthalmology, and outpatient settings
- Purchasing contracts and group purchasing organization decisions
- Periodic shortages or allocation of injectable products
The product may benefit when hospitals seek lower-cost alternatives to recombinant hyaluronidase. It may lose share when institutions prefer human recombinant products for immunogenicity, sourcing, or formulary reasons.
What is Amphadase’s financial trajectory?
Amphastar does not separately report Amphadase net revenue, units sold, gross profit, or operating income in its public financial statements. The company reports revenue by broader product categories and major commercial products, but Amphadase is not generally presented as a standalone material reporting segment. (Amphastar Pharmaceuticals, Inc., 2024)
As a result, the following metrics cannot be calculated reliably from public filings:
- Annual Amphadase revenue
- Year-over-year Amphadase growth
- Product-specific gross margin
- Amphadase contribution to Amphastar earnings
- Amphadase market share
- Product-specific sales concentration
- Return on manufacturing investment
The most supportable financial assessment is qualitative:
| Financial factor |
Assessment |
| Revenue scale |
Small relative to Amphastar’s consolidated portfolio |
| Growth profile |
Mature and procedure-linked |
| Margin potential |
Potentially attractive if manufacturing costs and competition remain controlled |
| Volume volatility |
Moderate; affected by institutional purchasing and procedures |
| Pricing power |
Limited by Hylenex and hospital procurement |
| Capital intensity |
Lower than for a newly developed biologic, but sterile manufacturing remains demanding |
| Strategic role |
Portfolio diversification and recurring niche revenue |
| Financial risk |
Low absolute exposure, but vulnerable to substitution and supply interruptions |
Amphastar’s larger products, including Baqsimi, Primatene MIST, glucagon, epinephrine, naloxone, and other hospital products, have a greater influence on consolidated financial results. Amphadase is best viewed as a legacy portfolio asset rather than a primary earnings catalyst.
How strong is the Amphadase patent estate?
Amphadase appears to have limited current patent leverage. The product’s approved use dates to 2004, and the commercially relevant composition and use concepts are longstanding. Any historical formulation or manufacturing patents would likely have reached the end of their practical exclusivity period unless protected by unusually late patent term adjustment or a later improvement patent.
The more meaningful barriers are technical:
Manufacturing and intellectual-property barriers
Manufacturing a sterile hyaluronidase product requires control of:
- Animal-derived starting material
- Protein purification
- Enzyme activity and potency
- Microbial and viral safety
- Sterility assurance
- Stability during storage
- Container and delivery-system compatibility
These controls can delay or increase the cost of entry, but they do not create the same barrier as an active composition-of-matter patent. A competitor with an established sterile injectable platform could potentially enter if market economics justify development costs.
Are generic or biosimilar challenges likely?
A conventional generic challenge would face a limited opportunity because Amphadase is a biologically derived enzyme product with manufacturing characteristics that may not be fully captured by a simple small-molecule ANDA pathway. A competing product could require a more complex regulatory strategy, depending on FDA classification and the scope of the reference-product comparison.
A biosimilar challenge is also not the most direct risk. Amphadase is not a typical reference biologic with a large patent-protected market. The more plausible competitive threat is a separately developed hyaluronidase product, particularly one using recombinant human technology or a lower-cost animal-derived process.
The commercial risk hierarchy is therefore:
- Formulary substitution to Hylenex
- New recombinant hyaluronidase entry
- Manufacturing or supply disruption
- Hospital price pressure
- Conventional patent litigation
What generic launch scenarios exist for Amphadase?
Base case: continued niche sales
Amphadase remains available through Amphastar, with stable but modest demand. Pricing remains constrained, while recurring hospital and outpatient use supports a durable revenue stream.
Downside case: formulary migration
Hospitals shift toward Hylenex because of preference for recombinant human hyaluronidase. Amphadase volume declines, particularly in systems with centralized procurement and standardized product protocols.
Upside case: value-driven substitution
Hospitals use Amphadase as a lower-cost alternative during budget pressure or recombinant-product supply constraints. The product gains volume without achieving high growth because total hyaluronidase utilization remains limited.
Entry case: new competitor
A new manufacturer introduces a competing hyaluronidase product. Amphadase faces price erosion, contract rebidding, and increased documentation requirements. The impact depends on whether the entrant offers recombinant sourcing, lower pricing, or improved availability.
What licensing deals and litigation affect Amphadase?
No major publicly disclosed licensing transaction or high-profile patent litigation appears to define Amphadase’s current commercial position. Amphastar’s relationship with the product is primarily that of the marketed-product owner and manufacturer.
The absence of major litigation is consistent with a mature, low-revenue product whose market may not support expensive patent enforcement. The primary business issues are likely supply, procurement, manufacturing compliance, and competitive positioning rather than courtroom disputes.
What is the commercial outlook for Amphadase?
Amphadase has a durable but constrained outlook. Its age eliminates meaningful statutory exclusivity, while its niche indications limit the size of the market. The product can continue generating recurring revenue if Amphastar maintains supply reliability and remains competitive with Hylenex.
The key value drivers are cost of goods, institutional contracts, product availability, and customer acceptance of bovine-derived hyaluronidase. The key risks are substitution by recombinant human hyaluronidase and the entry of a lower-cost or better-positioned competitor.
For investors and licensing teams, Amphadase should be modeled as a small, mature specialty product. It should not be assigned the growth profile or valuation framework used for Amphastar’s newer branded products or pipeline assets.
Key Takeaways
- Amphadase is a 150 USP units/mL bovine hyaluronidase product marketed by Amphastar.
- FDA approval dates to 2004 under NDA 021664.
- Its main competitor is Hylenex recombinant from Halozyme.
- Amphadase has no meaningful remaining statutory exclusivity based on its approval age.
- Public filings do not separately disclose Amphadase revenue or profitability.
- The product’s financial trajectory is therefore best characterized as mature, niche, and procedure-linked.
- Manufacturing quality, sterile supply, hospital contracts, and pricing are more important than patent protection.
- The largest commercial risk is formulary substitution, not Paragraph IV litigation or biosimilar entry.
- Amphadase is likely a recurring portfolio contributor but not a material driver of Amphastar’s consolidated growth.
FAQs About Amphadase Market and Financial Outlook
Is Amphadase a biologic or a generic drug?
Amphadase is a biologically derived hyaluronidase product approved as a prescription drug. It is not a conventional small-molecule generic and is not a biosimilar to Hylenex.
Who manufactures Amphadase?
Amphadase is marketed by Amphastar Pharmaceuticals, a U.S. specialty pharmaceutical company focused on injectable, inhaled, and other complex products.
Is Amphadase interchangeable with Hylenex?
The products have the same labeled strength but different sources of hyaluronidase. Amphadase is bovine-derived, while Hylenex is recombinant human hyaluronidase. Automatic interchangeability should not be assumed solely from matching unit strength.
Does Amphadase have active patent protection?
Amphadase’s commercial position does not appear to depend on a material current patent estate. Its approval dates to 2004, and its principal competitive barriers are manufacturing, supply, and institutional procurement.
Could Amphadase revenue materially affect Amphastar’s valuation?
Based on public disclosure, Amphadase is unlikely to be a material standalone driver of Amphastar’s valuation. Its value is more consistent with a recurring niche product that supports portfolio breadth and manufacturing utilization.
References
-
Amphastar Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2004). Amphadase (hyaluronidase injection) prescribing information, NDA 021664. FDA.
-
U.S. Food and Drug Administration. (n.d.-a). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs database. FDA.
-
U.S. National Library of Medicine. (n.d.). DailyMed: Amphadase hyaluronidase injection, solution. National Library of Medicine.
